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812Objective: We aimed to evaluate the efficacy and safety of a cold crystalloid cardioplegic solution with aden-
osine (1.2 mmol/L) instead of supranormal potassium.
Methods: Sixty low-risk patients scheduled for elective coronary artery bypass grafting (CABG) were random-
ized to receive standard cold crystalloid hyperkalemic cardioplegia (hyperkalemic group) or normokalemic car-
dioplegia in which supranormal potassium was replaced with 1.2 mmol/L adenosine (adenosine group). End
points were postoperative release of troponin T and creatine kinase MB, hemodynamics measured by PiCCO
arterial thermodilution catheters, perioperative release of markers of endothelial activation and injury, and clin-
ical course.
Results: The adenosine group had a significantly shorter time to arrest than did the hyperkalemic group (mean
 standard deviation, 11 5 vs 44 18 seconds; P<.001). Three hearts in the adenosine group were probably
not adequately drained and received additional hyperkalemic cardioplegia to maintain satisfactory cardioplegic
arrest. There were no differences between groups with respect to perioperative release of markers of endothe-
lial activation or injury and no differences between groups in postoperative release of troponin T or creatine
kinase MB. Postoperative hemodynamics including cardiac index were similar between groups. The incidence
of postoperative atrial fibrillation was significantly lower in the adenosine group than in the hyperkalemic
group (4 vs 15; P ¼ .01).
Conclusions: Adenosine instead of hyperkalemia in cold crystalloid cardioplegia is safe, gives more rapid car-
diac arrest, and affords similar cardioprotection and maintenance of hemodynamic parameters, together with
a marked reduction in the incidence of postoperative atrial fibrillation. (J Thorac Cardiovasc Surg
2013;145:812-8)We1,2 have previously shown in experimental studies that
replacement of potassium with adenosine in cold crystalloid
cardioplegia resulted in improved postcardioplegic left
ventricular systolic function and energetics, attenuated
myocardial cell damage, and improved preservation of
endothelial function through the endothelium-derived
hyperpolarizing factor pathway. It has been shown in a clin-
ical trial that administration of adenosine (0.25 mg/kg) just
before administration of standard hyperkalemic cardiople-
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The Journal of Thoracic and Cardiovascular Surgcardioplegic arrest, less release of creatine kinase MB iso-
enzyme (CK-MB) during the operation, and significantly
better preservation of cardiac function in the first postoper-
ative phase.3 Administration of adenosine immediately af-
ter aortic crossclamp release in valve surgery with
standard hyperkalemic cardioplegia has also been shown
to be related to reduced troponin I release, reduced inotropic
drug use, and shorter intensive care unit (ICU) stay.4 Both
phase I and phase II studies have been performed with
low doses of adenosine (up to 0.1 mmol/L) as an adjunct
to hyperkalemic blood cardioplegia showing that adenosine
could be safely administered during cardiopulmonary by-
pass (CPB). However, in these studies there was no proof
of improved cardioprotection.5,6 Others have shown that
higher doses of adenosine (2 mmol/L) as an adjunct to
hyperkalemic blood cardioplegia was well tolerated and
improved cardioprotection as revealed by less myocardial
ischemia and a trend to less use of inotropic drugs.7 In
pediatric cardiac surgery the combination of lidocaine and
adenosine in moderate potassium (10 mmol/L) cardioplegia
was superior regarding postoperative pulse pressure
and release of troponin I compared with hyperkalemic
cardioplegia and with hyperkalemic (20 mmol/L)ery c March 2013
Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
CK-MB ¼ creatine kinase MB isoenzyme
CPB ¼ cardiopulmonary bypass
DC shock ¼ direct-current countershock
ICU ¼ intensive care unit
t-PA ¼ tissue-plasminogen activator
Jakobsen et al Perioperative Managementadenosine–lidocaine cardioplegia.8 An in vitro study using
the combination of adenosine and lidocaine with varying
concentrations of potassium has indicated that normokale-
mic conditions are favorable regarding postischemic recov-
ery and arrhythmias.9 However, to our knowledge no
clinical studies have yet investigated the use of adenosine
in a cardioplegic solution with normal potassium concentra-
tion, and such studies have been requested.10 The primary
objective of this study was therefore to evaluate the efficacy
and safety of a cold crystalloid cardioplegic solution with
adenosine (1.2 mmol/L) instead of supranormal potassium.P
MMETHODS
Sixty patients scheduled for elective coronary artery bypass grafting
(CABG) at the University Hospital of North Norway were in the period be-
tween April 2010 andMarch 2011 randomized to receive either St Thomas’
Hospital solution (hyperkalemic group) or a solution in which hyperkale-
mia was replaced with 1.2 mmol/L adenosine (adenosine group). The solu-
tions were otherwise similar, including procaine hydrochloride and
magnesium content. The randomization was performed by using an exter-
nally administered randomization program (Microsoft Access; Microsoft
Corporation, Redmond, Wash). So that an even distribution of the 2 regi-
mens with time could be ensured, the patients were block randomized
with random block size including 4, 6, or 8 patients in each block. Exclu-
sion criteria were preoperative left ventricular ejection fraction below
40%, age above 75 years, pregnancy, and concomitant or emergency pro-
cedures. The study was approved by the regional ethics committee and the
NorwegianMedicines Agency. All patients provided written informed con-
sent before trial enrollment. The trial is registered in www.clinicaltrials.
gov, with the clinicaltrials.gov ID: NCT01123525.
Anesthesia was induced with intravenous fentanyl, midazolam, and
thiopental. Vecuronium was used for muscle relaxation. Fentanyl and iso-
flurane in a mixture of oxygen and air were used for analgesia and anesthe-
sia maintenance before and after CPB. Propofol was used as anesthesia
maintenance during CPB. Heparin was given to achieve a target activated
clotting time of 480 seconds or more before commencing CPB. The as-
cending aorta was cannulated and venous drainage was obtained from
a cavoatrial cannula. A coronary sinus catheter was inserted retrogradely
through a purse-string suture in the right atrium and placed toward the great
cardiac vein for blood sampling. Circuits were coated with Bioline polymer
(Jostra Medizintechnik, Hirrlingen, Germany) and primed with 1800 mL
Ringer acetate. A Quadrox oxygenator (Maquet Cardiopulmonary AG,
Hirrlingen, Germany) and a St€ockert S5 roller pump (St€ockert GmbH, Frei-
burg, Germany) were used. Similar-looking 100-mL vials with concen-
trated cardioplegic solution were diluted in 900-mL cold Ringer acetate;
final concentrations are given in Table 1. Cardioplegic solution was given
in a double-blind randomized manner in which only the hospital pharmacy
knew which solution was given to each patient. After aortic crossclamping,
cardioplegic arrest was initiated with 750 mL of cold (4C-6C) crystalloid
cardioplegic solution delivered antegradely into the aortic arch. IfThe Journal of Thoracic and Cacardioplegia was unsatisfactory after 5 minutes, judged by the surgeon,
the resulting 250 mL of cardioplegic solution was given. If cardiac arrest
was still unsatisfactory, the surgeons were allowed to convert to standard
hyperkalemic cardioplegia. Cardioplegic arrest was maintained with 200
mL of cardioplegic solution every 20 minutes. After weaning from CPB,
3 mg/kg of protamine was administered to reverse antiocoagulation.
PiCCO technology (Royal Phillips Electronics, Amsterdam, the Nether-
lands) was used for preoperative and postoperative hemodynamic monitor-
ing and intermittent cardiac output measurements with thermodilution
technique using a femoral artery catheter and central venous catheter. Car-
diac output measurements were assessed in a steady state situation after an-
esthesia was induced but before surgery, immediately after sternal closure,
at ICU arrival, and then repeatedly during the first 12 hours in the ICU.
Blood samples (CK-MB, troponin T, creatinine, myoglobin, and elec-
trolytes) were obtained the morning before surgery, at ICU arrival, and 4,
8, 12, 18, 24, 36, and 48 hours postoperatively. Perioperative blood samples
(white blood cells, interleukin 6, intercellular adhesion molecule, vascular
cell adhesion molecule and tissue-plasminogen activator [t-PA] antigen)
were simultaneously sampled from the cardioplegia cannula in the aorta
and a catheter in the coronary sinus twice; just before crossclamping the
aorta and after 5 minutes of reperfusion. Release of troponin T and CK-
MB was prespecified as primary end points whereas the other end points
were secondary outcome measures.
Statistics
Data are presented as mean standard deviation. Data were analyzed in
a statistical software package PASW statistics 18 (SPSS Inc, Chicago, Ill).
A 50% difference between groups was considered significant to calculate
sample size. On the basis of a previous study,11 together with an
experience-based estimate of patients lost to follow-up because of reoper-
ation owing to bleeding, our study with 60 patients would ensure power
greater than 80 with a P value of .05. Analyses of between-group differ-
ences were done by using analysis of variance and analyses of repeated
measures by using analyses of variance for repeated measures. Categorical
data were analyzed by the c2 table and by using Fisher’s exact probability
test. Operative and postoperative data from the patients receiving both hy-
perkalemic and adenosine cardioplegia were excluded. Postoperative data
from blood samples and PiCCOmeasurements from the patients reoperated
on owing to bleeding were also excluded.
RESULTS
Preoperative
Preoperative data are given in Table 2. There were no
differences in gender, age, or weight preoperatively. The
hyperkalemic group had a significantly higher level of
blood creatinine before surgery. There were no between-
group differences in the number of patients treated with
beta-blockers or angiotensin converting enzyme I/angioten-
sin II receptor antagonists.
Perioperative Results
Time on CPB and crossclamp time was similar between
groups (Table 2). There was a significantly shorter time to
cardioplegic arrest in the adenosine group than in the hyper-
kalemic group (11  5 vs 44  18 seconds). There were no
differences between groups with respect to volume of cardi-
oplegic solution given, time on CPB, crossclamp time, or
number of distal anastomoses (Table 2). Three patients in
the adenosine group were converted to hyperkalemic cardi-
oplegia owing to unsatisfactory arrest as judged by therdiovascular Surgery c Volume 145, Number 3 813
TABLE 1. Composition of the cardioplegic solutions in final
concentration (mmol/L)
Hyperkalemic
cardioplegia
(hyperkalemic group)
Adenosine
cardioplegia
(adenosine group)
Potassium chloride 20 4
Magnesium chloride 17 17
Procaine hydrochloride 1 1
Calcium chloride 2 2
Sodium acetate 30 30
Sodium chloride 100 100
Adenosine 0 1.2
pH 5-6 5-6
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Msurgeon. Spontaneous rhythm after removal of the aortic
crossclamp was achieved in 27 patients in the hyperkalemic
group versus 18 in the adenosine group (P ¼ .05). ThreeTABLE 2. Patient charachteristics
Patient charachteristics
Hyperkalemic
cardioplegia
Adenosine
cardioplegia
P
value
Preoperative n ¼ 30 n ¼ 30
Age 64.0  6.8 63.3  7.1 NS
Female/male 2/28 3/27 NS
Weight 87.3  15.4 86.0  16.4 NS
Creatinine 98.6  44.0 78.5  11.7 .02
Treated with beta-blocker 27 22 NS
Treated with ACE-I/AII
antagonist
16 12 NS
Atrial fibrillation 1 3
Operative n ¼ 30 n ¼ 27
Time to arrest (s) 44  18 11  5 <.001
Crossclamp time (min) 43  18 47  17 NS
Time on CPB (min) 75  24 82  27 NS
Distal anastomoses 3.4  1.0 3.4  0.8 NS
Volume of cardioplegia
(mL)
1087  260 1181  266 NS
Perioperative myocardial
infarction
0 0 NS
Spontaneous rhythm 27 18 .05
Potassium injection/DC
shocks
2/1 3/6 NS/0.04
Postoperative n ¼ 30 n ¼ 27
Reoperated on owing to
bleeding
2 3 NS
n ¼ 28 n ¼ 24
Time on ventilator (min) 186  103 169  90 NS
Treatment with inotropics/
pressor
1 1 NS
Nitrogen infusion 1 2 NS
New-onset atrial
fibrillation<4 d
15/28 4/21 .01
Operative date from 27 patients in the adenosine group are given inasmuch as 3 pa-
tients received both adenosine and hyperkalemic cardioplegia. Postoperative data
from the patients reoperated on owing to bleeding are excluded. Data are given in
mean  standard deviation. NS, Not significant; ACE-I/AII, angiotensin converting
enzyme I–angiotensin II; CPB, cardiopulmonary bypass; DC shock, direct-current
countershock.
814 The Journal of Thoracic and Cardiovascular Surghearts in the adenosine group and 2 in the hyperkalemic
group converted to sinus rhythm after potassium injection,
whereas 6 patients in the adenosine group versus 1 in the
hyperkalemic group needed additional direct-current coun-
tershocks (DC shocks) to convert to sinus rhythm (Table 2).
The results from the perioperative blood samples from the
aorta and the coronary sinus are displayed in Table 3. There
was a significant increase in white blood cells and t-PA
antigen both in arterial blood and in the coronary sinus in
both groups, and a significant increase of vascular cell adhe-
sion molecule in the coronary sinus in the adenosine group.
No differences between groups were however revealed.
Postoperative Results
Three patients in the adenosine group and 2 patients in
the hyperkalemic group needed temporary cardiac pacing
owing to bradycardia for the first postoperative hours,
18 hours at most. Three patients in the adenosine group
and 2 patients in the hyperkalemic group were reoperated
on owing to bleeding. One patient in the hyperkalemic
group received treatment with norepinephrine for the first
21 hours postoperatively, and 1 patient in the adenosine
group received treatment with dobutamine between 8 and
18 hours postoperatively. Four of 21 patients in the adeno-
sine group had postoperative new-onset atrial fibrillation
(3 patients with preoperative atrial fibrillation, 2 patients re-
operated on owing to bleeding, and the 3 patients converted
to hyperkalemic cardioplegia excluded), and 15 of 28 pa-
tients in the hyperkalemic group had postoperative new-
onset atrial fibrillation (2 patients reoperated on owing to
bleeding excluded, 1 of them with preoperative atrial fibril-
lation). There were no differences between groups with re-
spect to postoperative release of troponin T or CK-MB
(Figure 1) or myglobin (data not shown). There were no dif-
ferences between groups in postoperative creatinine, but
the hyperkalemic group had a significantly higher value
of cystatin C 12 and 24 hours postoperatively (in milli-
grams per liter: hyperkalemia, 0.79  0.30 and
0.87  0.33 vs adenosine, 0.64  0.13 and 0.70  0.13;
P ¼ .04 and .02 respectively) and also higher value of po-
tassium 24 hours postoperatively (4.4  0.4 vs 4.1  0.3;
P ¼ .04).
There were no differences between groups before or after
surgery in cardiac index or systemic vascular resistance and
no differences in postoperative heart rate or mean arterial
pressure (Figure 2). Also, there were no differences
between groups in central venous pressure or global
end-diastolic volume index (data not shown).
DISCUSSION
Adenosine instead of hyperkalemia in the cardioplegic
solution provided adequate, and even more rapid, cardiac
arrest in 27 of 30 patients. In the 3 patients who were con-
verted to hyperkalemic cardioplegia, different reasonsery c March 2013
TABLE 3. Results from the perioperative arterial and coronary sinus blood samples, taken immediately before crossclamping the aorta and after 5
minutes of reperfusion
Group
Before crossclamp After 5 minutes of reperfusion
Arterial Coronary sinus Arterial Coronary sinus
WBC (109/L) K 4.53  1,48 4.40  1.68 9.18  3.04* 8.36  2,80*
A 3.98  1.60 3.82  1.64 8.34  3.03* 7.38  2.61*
t-PA antigen (ng/mL) K 7.36  3.94 8.50  3.32 10.86  4.94* 13.17  5.81*
A 5.99  1.96 7.28  3.35 10.60  5.04* 12.05  5.93*
ICAM (pg/mL) K 200  97 183  120 181  94 179  79
A 136  65 117  59 135  87 123  45
VCAM (pg/mL) K 659  528 675  426 857  490 772  346
A 623  346 581  275 787  338 741  267*
P-selectin (pg/mL) K 33.9  11.0 31.7  12.1 31.1  10.2 33.2  8.3
A 28.9  8.9 26.6  7.8 28.4  10.1 28.1  7.2
E-selectin (pg/mL) K 28.6  13.0 28.0  14.3 25.4  10.1 26.1  9.9
A 22.7  10.6 21.5  10.9 22.3  13.9 20.3  11.0
Data are given in mean  standard deviation. Patients receiving both hyperkalemic and adenosine cardioplegia are excluded. No between-group differences were revealed.
A, Adenosine group (n ¼ 27); K, hyperkalemic group (n ¼ 30); WBC, white blood cells; t-PA, tissue-plasminogen activator; ICAM, intercellular adhesion molecule;
VCAM, vascular cell adhesion molecule. *Significant compared with baseline values (within group).
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Mwere given. In the first patient, cardiac arrest was achieved
with adenosine cardioplegia within 2 seconds after admin-
istration. However, after 4 to 5 minutes of arrest the heart
resumed contractions, and according to the protocol more
adenosine cardioplegia was given and cardiac arrest was
again achieved. The heart again reanimated after 5 addi-
tional minutes, and therefore hyperkalemic cardioplegia
was given. In this patient the surgeon noticed retrograde
bleeding from the coronary arteries, so washout of the
cardioplegic solution, together with more rapid rewarm-
ing, is suspected, likely owing to unsatisfactory emptying
of the pulmonary vascular bed before clamping and/or
poor venous drainage. In the second patient, cardioplegia
was achieved after 13 seconds, but after administration of
500 mL of cardioplegic solution, ventricular fibrillation
was observed and was still present after 1000 mL ofFIGURE 1. Release of troponin T and creatine kinase MB (CKMB) preoperati
lemic cardioplegia (closed circles, n¼ 28) or cardioplegia with 1.2 mmol/L of a
given as mean and error bars denote standard deviation. Patients reoperated on
cardioplegia are excluded.
The Journal of Thoracic and Cacardioplegic solution. According to the protocol, hyperka-
lemic cardioplegic solution should then have been given if
the arrest was unsatisfactory 5 minutes after administra-
tion of the cardioplegia. However, it was converted to hy-
perkalemic cardioplegia immediately, so the protocol was
not strictly followed. In the third patient, ventricular fi-
brillation was observed 10 seconds after administration
of adenosine cardioplegia and was still present after 750
mL. Another 250 mL was therefore given and the cardio-
plegia was satisfactory. After 10 minutes of cardioplegia,
the heart started to fibrillate again, and then hyperkalemic
cardioplegic solution was given. This patient was known
to have aortic insufficiency. We therefore conclude that
the use of adenosine instead of hyperkalemia in the cardi-
oplegic solution gives a more rapid cardiac arrest, but the
maintenance of cardiac arrest seems more susceptible tovely (pre) and 0 to 48 hours postoperatively in patients receiving hyperka-
denosine instead of supranormal potassium (open circles, n¼ 24). Data are
owing to bleeding and patients receiving both adenosine and hyperkalemic
rdiovascular Surgery c Volume 145, Number 3 815
FIGURE 2. Cardiac index and systemic vascular resistance index measured immediately before surgery (preop), after sternal closure (postop), immedi-
ately after arrival at the intensive care unit (arrival ICU), and 4, 8, and 12 hours after arrival at the ICU. Heart rate and mean arterial pressure were measured
immediately after arrival at the ICU and 4, 8 and 12 hours after arrival at the ICU. All parameters were measured with PiCCO arterial thermodilution cath-
eters in patients receiving either hyperkalemic cardioplegia (closed circles, n¼ 28) or adenosine cardioplegia (open circles, n¼ 24). Data are given as mean
and error bars denote standard deviation. Patients reoperated on owing to bleeding and patients receiving both adenosine and hyperkalemic cardioplegia
were excluded.
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Mwashout of the cardioplegic solution from the coronary ar-
teries and mixing with normothermic blood.
We could not detect any differences in postoperative
release of CK-MB or troponin T, and the postoperative
hemodynamic measurements including cardiac index
were similar between groups. This study included patients
having elective CABG with ejection fraction above 40%,
no recent myocardial infarction, and age below 75 years.
This means low-risk patients with short aortic crossclamp
time. Inasmuch as the ischemic period is short and these
hearts supposedly tolerate the ischemic period well, a differ-
ence in cardioprotection with the end points we used could
hardly be expected. This is also reflected in the results with
no postoperative mortality, low postoperative morbidity,
together with high postoperative cardiac outputs. However,
to our knowledge this is the first study to investigate the
efficacy and safety of adenosine instead of hyperkalemia
in cardioplegia, and we therefore found it important to do
the first clinical study in a low-risk population.816 The Journal of Thoracic and Cardiovascular SurgThere was a higher postoperative value of cystatin C in
the hyperkalemic group, but since we did not measure pre-
operative cystatine C and the preoperative value of creati-
nine also was higher in the hyperkalemic group, we
cannot conclude with any differences in renal protection
between the 2 cardioplegic solutions. Also, therewas no dif-
ference between groups in postoperative creatinine when
compared with baseline values. The role of postischemic
perivascular inflammation in postischemic cardiac injury
is generally accepted as important, and the interaction
between white blood cells and the endothelium is a key
step in this inflammatory process. We2 have previously
shown in a large animal model that adenosine instead of
supranormal potassium in the cardioplegic solution
improves postcardioplegic endothelium-derived hyperpo-
larization factor–dependent vasodilation. We therefore
wanted to measure markers of endothelial activation and
injury, results given in Table 3. We found higher values of
white blood cells and t-PA antigen in both groups afterery c March 2013
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M5 minutes of reperfusion, but these results did not add any
sensitivity to our end point measurements.
Six patients in the adenosine group, versus 1 in the hyper-
kalemic group, needed DC shocks because of ventricular
fibrillation refractory to extra potassium injections in the re-
perfusion period. Two of the patients needed 2 DC shocks,
and 1 needed 3 DC shocks to gain sinus rhythm. This did not
lead to any problems with weaning from CPB in any of the
patients or any increase in the release of troponin T or
CK-MB in the adenosine group. However, ventricular fibril-
lation during the reperfusion and rewarming period may
contribute to myocardial damage owing to increased myo-
cardial oxygen consumption and decreased subendocardial
blood flow. Adenosine is a potent vasodilator, and we2 have
previously shown in the preclinical study that endothelium-
derived hyperpolarization factor–dependent vasodilation
was better preserved in the adenosine group than in the hy-
perkalemic group. Reperfusion arrhythmias are suggested
to be due to abrupt washout of toxic metabolites, and de-
creased arrhythmias are reported with reduced rates of
reperfusion.12 A theoretical explanation might therefore
be that the hearts in the adenosine group have a more dilated
coronary vascular bed; hence these hearts are more suscep-
tible to rapid crossclamp release and need a gentler
reperfusion.
New-onset atrial fibrillation remains the most common
complication after cardiac surgery; its peak incidence is
between the second and third postoperative days. In larger
patient series it is reported to occur in 25% to 40% of pa-
tients after CABG and in up to 62% after combined
CABG and valve surgery.13 New-onset atrial fibrillation is
widely known to increase morbidity after cardiac sur-
gery,14,15 and a recent meta-analysis has shown that new-
onset atrial fibrillation after CABG appears to increase
short- and long-termmortality.15 Atrial fibrillation after car-
diac surgery is also an independent risk factor of delayed
stroke,16 lengthening hospitalization and increasing the
overall expenses of cardiac surgery. If changing the cardio-
plegic solution could reduce the incidence of atrial fibrilla-
tion after cardiac surgery, it would be a major improvement
in the handling of patients undergoing cardiac surgery.
New-onset atrial fibrillation occurred in only 4 (19%) of
21 patients in our adenosine group versus 15 (54%) of
28 in our hyperkalemic group (P ¼ .01). The pathophysiol-
ogy of atrial fibrillation after heart surgery is not known, but
its etiology is thought to be multifactorial. Abnormal elec-
tophysiologic state of the atria, unequal shortening of the
atrial myocytes refractory period, ischemia of the atrial tis-
sue, increased sympathetic activation, and exaggerated
inflammatory response have been suggested to play trigger-
ing roles.17 With largely unknown pathophysiology, any
suggested mechanisms behind the lowered incidence of
atrial fibrillation must be speculative. Our results demon-
strate no difference in global ischemia or inflammatoryThe Journal of Thoracic and Caresponse, but the atria have not been studied exclusively.
The cardioplegic solution with adenosine instead of hyper-
kalemia does, however, give a nondepolarizing arrest with
several theoretical advantages concerning the electrophysi-
ology, as a more balanced transmembrane ion gradient and
a reduction in ionic imbalance. Adenosine has little or no
effect on the duration of ventricular action potential18,19
but shortens the action potential in atrial myocardium and
attenuates the increase in action potential duration often
seen after stimulation with catecholamines.18 Afterdepola-
rizations and triggered arrhythmic activity induced by cate-
cholamines are also attenuated or abolished by adenosine,20
and the anti-b-adrenergic effect, which is shown to be pro-
longed after administration of adenosine,21 may possibly
reduce the rate of postoperative atrial fibrillation.
There were different surgeons operating on the study
patients, with some variations in both experience and surgi-
cal techniques, which leads to some variation in crossclamp
time and time on CPB. The patients also had different
degrees of coronary disease and hence perhaps also differ-
ent degrees of coronary distribution of the cardioplegic
solutions. Both these factors result in an increased variance
in the degree of both global and local ischemia. A more
strict selection of patients with more homogenous coronary
disease, together with fewer surgeons, could have lowered
the variance and hence strengthened the study. Another lim-
itation with our study is that inasmuch as the incidence of
postoperative atrial fibrillation was not a primary end point,
the patients were only monitored with continuous electro-
cardiography during the stay at the ICU, and thereafter
once daily or when the patients had symptoms indicating
atrial fibrillation. We can therefore not exclude that some
patients had short episodes with asymptomatic atrial fibril-
lation that we have not registered. A future larger scale
study to confirm our results should therefore include contin-
uous postoperative electrocardiographic monitoring, and
the patient population should be more homogeneous. The
ideal population might be patients going through isolated
aortic valve replacement and also with preoperative
impaired ventricular function. These patients are more in
need for an improved cardioplegic solution, and an
improvement will be better detectable. Such a patient group
will also be more homogeneous with respect to crossclamp
time, time on CPB, and coronary distribution of the cardio-
plegic solution, which again will lower the variance in both
global and local ischemia. This population does also have
a higher incidence of postoperative atrial fibrillation, and
a reduction of this will therefore be even more convincing.
Blood cardioplegia is generally accepted as superior to
crystalloid cardioplegia, although the superiority is scant,22
still debated,23 and a large-scale randomized study with
CABG patients failed to prove superiority.24 Adenosine in-
stead of hyperkalemia in blood cardioplegia leads to some
extra challenges owing to its rapid metabolism in blood,rdiovascular Surgery c Volume 145, Number 3 817
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Concentrations of adenosine greater than 0.2 mmol/L
inhibit adenosine deaminase, concentrations greater than
10 mmol/L inhibit adenosine kinase in intact human eryth-
rocytes, and hypothermia also inhibits adenosine metabo-
lism.25 Sufficient doses of adenosine instead of
hyperkalemia in hypothermic blood cardioplegia could
therefore both give acceptable cardioplegia and activate
the cardioprotective mechanisms. The question of optimal
dose is an unresolved issue. A method with a different
line for delivery of adenosine can also be used to avoid
the challenge with breakdown of adenosine. The future
larger-scale study, as suggested earlier, should perhaps be
performed with blood cardioplegia inasmuch as this is gen-
erally more accepted as today’s gold standard cardioplegic
regimen.
CONCLUSIONS
Adenosine instead of supranormal potassium in cold
crystalloid cardioplegia is safe and efficient provided ade-
quate drainage. In low-risk patients it results in similar car-
dioprotection with respect to release of cardiac enzymes
and similar preservation of hemodynamics and cardiac
index. When hyperkalemia is replaced with adenosine, the
cardioplegic arrest was significantly more rapid and the
incidence of postoperative atrial fibrillation was signifi-
cantly reduced. Further studies in high-risk patients and
more long-lasting procedures are warranted.
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